Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Mar 4;9(2):e00728. doi: 10.1002/prp2.728

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd, British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

The cytotoxicity and antiapoptotic effect of Nobiletin on H2C9 cardiomyocytes against OGD treatment. (A) Cell viability was analyzed by MTT assay on H9C2 cardiomyocytes pretreated with various concentrations of Nobiletin for 24 h. (*p < .05 vs. CTL; n = 6). (B) Representative immunoblots and analysis of cleaved caspase‐3 levels in H9C2 cardiomyocytes after 12 h OGD treatment in the presence or absence of 2 h Nobiletin pretreatments. The data were represented as the mean ± SEM. (*p < .05 vs. CTL, ^# p < .05 vs. OGD; n = 6). (C) Representative images and analysis of FITC‐Annexin V/PI double stain of H9c2 cardiomyocytes by flow cytometry. (**p < .01 vs. CTL, ***p < .001 vs. CTL, ^# p < .05 vs. OGD; n = 6)